^
Association details:
Biomarker:BRCA2 mutation
Cancer:Ovarian Cancer
Drug Class:PARP inhibitor
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: B - Late Trials
Source:
Title:

Comparative efficacy of first-line maintenance PARP inhibitors (PARPI) in advanced ovarian cancer (OC): A network meta-analysis

Published date:
09/14/2020
Excerpt:
PARPI significantly improved PFS in homologous-recombinant deficiency (HRD+), HRD-, BRCA mutation (BRCA+)...It also demonstrates that individual PARPI vary in frequency of AE≥3 as well as clinical efficacy across mutation subtypes.
Evidence Level:
Sensitive: C3 – Early Trials
Title:

Efficacy of poly (ADP-ribose) polymerase inhibitors monotherapy and the impact to subsequent platinum-based chemotherapy in breast cancer susceptibility genes1/2-mutated ovarian cancer patients with secondary platinum-sensitive relapse

Published date:
10/28/2023
Excerpt:
BRCA1/2-mutated patients with secondary platinum-sensitive relapse included in this study... Of note, 26 patients in control group were treated with PARPi...the results showed that both PARPi monotherapy after secondary platinum-sensitive relapse (Fig. 3, median PRS: 41.2 vs. 33.7 months, p=0.019) and post-line treatment with PARPi (Fig. 3, median PRS: 48.1 vs. 33.7 months, p=0.002) prolonged PRS in patients compared to those who had never used PARPi.
DOI:
https://doi.org/10.1186/s13048-023-01283-2
Evidence Level:
Sensitive: C3 – Early Trials
Source:
Title:

Bevacizumab versus PARP-inhibitors in women with newly diagnosed ovarian cancer: a network meta-analysis

Published date:
03/30/2022
Excerpt:
PARPi improved PFS significantly more than bevacizumab in women with a BRCAm (HR 0.47; 95% CI 0.36-0.60) and with HRD (HR 0.66; 95% CI 0.50-0.87)….PARPi exhibited the highest surface under the cumulative ranking probabilities value as the most effective treatment for PFS (PARPi vs. bevacizumab: 98% vs. 52% in the overall population with ovarian cancer; 100% vs. 50% in women with BRCAm; 100% vs. 50% in women with HRD)....In women with newly diagnosed ovarian cancer, PARPi might be more effective in terms of PFS compared to bevacizumab.
DOI:
10.1186/s12885-022-09455-x
Evidence Level:
Sensitive: C3 – Early Trials
Title:

PARP Inhibitor in Platinum-Resistant Ovarian Cancer: Single-Center Real-World Experience

Published date:
04/14/2021
Excerpt:
The efficacy of PARPi monotherapy was assessed in patients with relapsed high-grade serous ovarian carcinoma with gBRCAm....objective response rate (complete response plus partial response) was 47%, median progression-free survival was 8.2 months (5.3-11.3), and overall survival was 14.9 months (11.2-18.5).
DOI:
10.1200/GO.20.00269